12:00 AM
Nov 04, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Vantictumab: Phase Ib started

OncoMed began an open-label, dose-escalation, U.S. Phase Ib trial to evaluate vantictumab in combination with paclitaxel in about 20 patients with locally advanced or metastatic HER2-negative breast cancer. The company plans to...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >